Philips Medical Systems will launch the latest version of its JetStream Workspace at the Society of Nuclear Medicine meeting in San Diego next week.The enhanced product, Version 3.0, features new workflow and image-display capabilities. Incremental improvements have been made in cardiac, bone, renal, salivary, and brain imaging.
Philips Medical Systems will launch the latest version of its JetStream Workspace at the Society of Nuclear Medicine meeting in San Diego next week.
The enhanced product, Version 3.0, features new workflow and image-display capabilities. Incremental improvements have been made in cardiac, bone, renal, salivary, and brain imaging.
"There are a lot of little things that add up to a big improvement," said Deepak Malhotra, senior director of marketing and business development for Philips nuclear medicine.
Malhotra noted that this latest version of JetStream has more than 200 individual enhancements. Each is based on customer feedback obtained since the product was released in April 2005 as Version 2.0.
The newest version can be obtained in IDL programming language, which allows customers to develop and customize applications. The product, which is compatible with all of Philips' gamma cameras, will be available for delivery in fall.
Version 3.0, like its predecessor, will be available in configurations designed for general nuclear medicine, cardiac, and study review. The upgraded product will be available to all users, although general nuclear medicine customers will benefit the most, Malhotra said.
The software is essentially complete right now, Malhotra said, but there may be "a few tweaks" before it begins shipping commercially.
"We will go through extensive clinical validation at customer sites," he said. "Based on their feedback, we might make some last minute adjustments."
Philips is counting on getting advice from at least five clinical sites.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.